Overview

Trail Evaluating Apatinib With IMRT for Inoperable or Iodine Refractory Thyroid Cancer

Status:
Unknown status
Trial end date:
2020-05-01
Target enrollment:
Participant gender:
Summary
To determine the efficacy and safety of intensity modulated radiation therapy combined with apatinib for inoperable or iodine refractory thyroid cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Xiayun He, MD
Treatments:
Apatinib